Journal article
Comorbidity, age and overall survival in cetuximabtreated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care
TR Asmis, E Powell, CS Karapetis, DJ Jonker, D Tu, M Jeffery, N Pavlakis, P Gibbs, L Zhu, DA Dueck, R Whittom, C Langer, CJ O'Callaghan
Annals of Oncology | Published : 2011
Abstract
Background: The interplay between comorbidity, age and performance status (PS) as predictors of outcome in advanced colorectal cancer (ACRC) is poorly understood. We examined these factors as predictors of treatment toxicity and outcome in cetuximab-treated patients with ACRC. Patients and methods: Comorbidity was independently evaluated using the Charlson Comorbidity Index (CCI), a validated measure of comorbidity based on the presence of medical conditions weighted according to their effect on mortality. CCI score was correlated with clinical and outcome data. Results: Five hundred and seventy-two patients were included; 41% were ≥65 years and 25% had comorbidities at randomization. In mul..
View full abstractGrants
Funding Acknowledgements
TRA has acted on advisory boards for Bristol Myers Squibb, CSK has acted on advisory board and has received honoraria for seminar presentation for Merck Serono, DJJ has acted on advisory boards and has received honoraria for seminar presentation for Bristol Myers Squibb, NP has acted on advisory boards and has received honoraria and travel funding and provided expert testimony for Merck Serono, CL is an employee of Bristol Myers Squibb and owns stock in Bristol Myers Squibb.